Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support

Summary

TCN PATHS will recruit an anticipated 400 participants who are prescribed MOUD who are released from detention facilities. Each individual will be randomized to either 1) standard primary care (SPC) or 2) a Transitions Clinic Network (TCN) program primary care. Participants will be followed for a year and complete surveys at baseline and at month 1, 3, 6, 9, and 12. At each of these points research staff will confirm MOUD status. Urine drug screenings will be completed at baseline, month 1, 6, and 12 if the participant is not incarcerated. When possible, research staff will collect electronic health records.

Conditions

• Opioid Addiction

Interventions

BEHAVIORAL

Transitions Clinic Network Primary Care

Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.

BEHAVIORAL

Standard Primary Care

Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.

Sponsors & Collaborators

• University of North Carolina

  collaborator OTHER

• University of Puerto Rico

  collaborator OTHER

• University of Rochester

  collaborator OTHER

• University of Miami

  collaborator OTHER

• University of California, San Francisco

  collaborator OTHER

• University of Connecticut

  collaborator OTHER

• Albert Einstein College of Medicine

  collaborator OTHER

• Hennepin Healthcare Research Institute

  collaborator OTHER

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Yale University

  lead OTHER

Principal Investigators

• Emily Wang, MD · Yale University

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-21

Primary Completion

2025-10-30

Completion

2025-12-30

Countries

• United States
• Puerto Rico

Study Locations